JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis; Sage touts double-duty anxiety drug

Welcome to Day 2 of the annual J. P. Morgan Healthcare Conference, gone virtual once more.

Here's your need to know. The deals began to flow as Amgen announced a team-up with Arrakis Therapeutics to develop a new class of RNA-targeting medicines, and Roche delivered a sizable investment in the liquid biopsy developer Freenome.